Podcast: Play in new window | Download (Duration: 14:50 — 6.8MB) | Embed
In this episode, we explore four unique antidepressants that do not fit neatly into the traditional SSRI or SNRI categories: trazodone, nefazodone, vilazodone, and vortioxetine. Trazodone and nefazodone are classified as serotonin antagonist and reuptake inhibitors (SARIs), working primarily through blockade of 5-HT2 receptors while also inhibiting serotonin reuptake. Trazodone’s strong antihistamine and alpha-1 blocking properties make it highly sedating and commonly used off-label for insomnia, whereas nefazodone causes less sedation but is rarely prescribed today because of its association with severe and potentially fatal liver toxicity. Both agents are notable for producing less sexual dysfunction than many traditional SSRIs.
We also discuss two newer multimodal antidepressants: vilazodone (Viibryd) and vortioxetine (Trintellix). Vilazodone combines serotonin reuptake inhibition with partial agonism at the 5-HT1A receptor, a mechanism often compared to combining an SSRI with buspirone. Vortioxetine has an even more complex pharmacology, acting as a serotonin reuptake inhibitor while modulating multiple serotonin receptor subtypes through agonist, partial agonist, and antagonist actions. This multimodal activity may contribute to benefits in cognitive symptoms associated with major depressive disorder. Throughout the episode, we compare receptor pharmacology, clinical applications, adverse effect profiles, and the unique characteristics that distinguish these medications from more commonly prescribed antidepressants.
Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!
Support The Podcast and Check Out These Amazing Resources!
Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated)
Guide to Drug Food Interactions (Amazon Best Seller)
